Illinois Municipal Retirement Fund Buys 15,533 Shares of Gilead Sciences, Inc. $GILD

Illinois Municipal Retirement Fund grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 321,286 shares of the biopharmaceutical company’s stock after buying an additional 15,533 shares during the period. Gilead Sciences accounts for 0.5% of Illinois Municipal Retirement Fund’s holdings, making the stock its 22nd biggest position. Illinois Municipal Retirement Fund’s holdings in Gilead Sciences were worth $47,888,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. BlackRock Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp lifted its position in Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares during the period. Amundi lifted its position in Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new stake in Gilead Sciences during the 2nd quarter worth about $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in Gilead Sciences during the 2nd quarter worth about $918,387,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Scotiabank boosted their price target on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. Barclays reduced their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Cantor Fitzgerald lifted their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Morgan Stanley lifted their target price on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Finally, Citigroup upped their target price on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $170.15.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares in the company, valued at approximately $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 9,810 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the sale, the chief executive officer directly owned 551,683 shares in the company, valued at approximately $96,638,311.11. The trade was a 1.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 242,709 shares of company stock worth $39,503,427 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $170.87 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The stock’s 50 day simple moving average is $154.00 and its two-hundred day simple moving average is $141.34. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. During the same period in the previous year, the firm earned $2.47 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Recent coverage highlights improving growth across Gilead’s business and strong recent results. Its latest reported quarter beat consensus on both earnings and revenue, with revenue up 6.8% year over year. This supports the positive investment case behind the stock’s advance toward a 52-week high. Article: Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
• Positive Sentiment: Analysts have recently raised price targets, including JPMorgan and Wells Fargo to $190, and maintained positive ratings—potential support for investor sentiment. Gilead Sciences analyst and stock information
• Neutral Sentiment: Gilead partner Xilio Therapeutics said it expects to deliver an option data package for its investigational cancer drug efarindodekin alfa to Gilead in the first half of 2027. Any value to Gilead depends on future data and potential payments; the update does not establish a near-term financial benefit. Xilio Therapeutics pipeline update
• Negative Sentiment: An executive vice president sold 3,399 shares, reducing his holdings by about 39%. The sale was made under a pre-arranged trading plan, which may limit its significance as a signal about the company’s outlook. Gilead Sciences insider-trading report
• Negative Sentiment: Vir, a competitor in hepatitis D, reported positive results for its experimental treatment. The news could raise competitive concerns, though the supplied report does not indicate an immediate impact on Gilead’s business. Vir rival advances hepatitis D treatment

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.